drugset / Trial / NCT05526001

Efficacy and Safety of ELIXCYTE Intra-articular Injection in Subject With Knee Osteoarthritis

NCT05526001 ↗

Phase 3 Active not recruiting 165 enrolled UnicoCell Biomed CO. LTD
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase III, double-blinded, placebo-controlled, multicenter study to investigate the efficacy and safety of a new study intervention, ELIXCYTE, compared to placebo (normal saline) in subjects with knee osteoarthritis. The primary hypothesis of the study is to demonstrate that ELIXCYTE is superior to placebo (saline) in improving knee pain on the target knee from baseline. During the study, each participant will receive either ELIXCYTE (study intervention) or placebo (normal saline) intra-articular injection once on the target knee after eligibility criteria check. The target knee will be assessed by X-ray, MRI and subject self-evaluation knee questionnaires (WOMAC, KSS and KOOS) in the following visits. Other safety assessments, including lab test, physical examination, vital sign, medical/medication history and adverse events will also be collected throughout the study.

Timeline

Start
2023-07-03
Primary completion
2026-05
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ELIXCYTE Cell therapy 4 ml Other
Subject ELIXCYTE Cell therapy 3.2e+07 cells Other

Indications